FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

By | November 21, 2022
On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.